InspireMD, Inc.

For the period ended Sep 30, 2025. Filed Nov 10, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 10, 2025

NSPR$0.71+2.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Equity

Common stock · Preferred C shares · Additional paid-in · Accumulated · Total
	Shares	Amount	Shares	Amount	capital	deficit	equity
BALANCE AT January 1, 2024	21,841,215	2	1,718	-*	261,000	(221,501)	39,501
Net loss	-	-	-	-	-	(22,831)	(22,831)
Exercise of pre-funded warrants	1,728,382	-*					-*
Exercise of Warrants Series H to 12,621,090 pre-funded warrants and 292,996 common stock, net of $1,000 issuance costs	292,996	1			16,853		16,854
Issuance of common shares, Included at the market offering net of $1 issuance costs	12,961				35		35
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 112,382 shares	1,844,078	-*			7,792		7,792
BALANCE AT September 30, 2024	25,719,632	3	1,718	-*	285,680	(244,332)	41,351

*	Represents an amount less than $1 thousand

Common stock · Preferred C shares · Additional paid-in · Accumulated · Total
	Shares	Amount	Shares	Amount	capital	deficit	equity
BALANCE AT July 1, 2024	25,196,479	3	1,718	-*	283,202	(236,442)	46,763
Net loss	-	-	-	-	-	(7,890)	(7,890)
Exercise of pre-funded warrants	199,992	-*					-*
Issuance of common shares, Included at the market offering net of $1 issuance costs	12,961				35		35
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award	310,200				2,443		2,443
BALANCE AT September 30, 2024	25,719,632	3	1,718	-*	285,680	(244,332)	41,351

*	Represents an amount less than $1 thousand

Common stock · Preferred C shares · Additional paid-in · Accumulated · Total
	Shares	Amount	Shares	Amount	capital	deficit	equity
BALANCE AT January 1, 2025	26,611,033	3	1,718	-*	289,589	(253,506)	36,086
Net loss	-	-	-	-	-	(37,025)	(37,025)
Exercise of pre-funded warrants	2,381,651	-*					-*
Issuance of common stock, included at the market offering and pre-funded warrants net of $3,148 issuance costs	7,510,293	1			38,713		38,714
Exercise of Warrants Series I to 10,561,685 pre-funded warrants and 2,352,393 common stock, net of $1,000 issuance costs	2,352,393	-*			16,855		16,855
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 322,919 shares	3,063,771	-*			9,484		9,484
BALANCE AT September 30, 2025	41,919,141	4	1,718	-*	354,641	(290,531)	64,114

*	Represents an amount less than $1 thousand

Common stock · Preferred C shares · Additional paid-in · Accumulated · Total
	Shares	Amount	Shares	Amount	capital	deficit	equity
BALANCE AT July 1, 2025	32,552,888	3	1,718	-*	298,063	(277,823)	20,243
Net loss	-	-	-	-	-	(12,708)	(12,708)
Exercise of pre-funded warrants	970,098	-*					-*
Exercise of Warrants Series I to 10,561,685 pre-funded warrants and 943,641 common stock, net of $891 issuance costs	943,641	-*			15,017		15,017
Issuance of common stock, included at the market offering and 9,764,804 pre-funded warrants net of $3,126 issuance costs	7,236,672	1			38,017		38,018
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 34,712 shares	215,842	-*			3,544		3,544
BALANCE AT September 30, 2025	41,919,141	4	1,718	-*	354,641	(290,531)	64,114

*	Represents an amount less than $1 thousand

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.